Sino Biological Anno...
14th September 2021 Content supplied by: Sino Biological US Inc.
200+ Recombinant SARS-CoV-2 Variants Bank for Vaccine Research
Recombinant antigens are key reagents in infectious disease research, which are widely used in therapeutic antibody and vaccine development.
Sino Biological has developed a panel of recombinant RBD/Spike and nucleocapsid protein variants, including Lambda (C.37), Delta (B.1.617.2, AY.1, AY.2, AY.3), Beta (B.1.351, B.1.351.2, B.1.351.3), and more Variants of Concern (VOCs) and Variants of Interest (VOIs).
The mutations in these strains also occur in the nucleocapsid protein, which is commonly used as the biomarker in rapid antigen tests. It’s critical to assess whether the current commercial antigen tests can detect the mutated N proteins with the same sensitivity and specificity as their WT counterpart.
Request Information using the button provided below or visit Sino Biological's website to find out more.
Date Published: 14th September 2021
Source article link: View
Sino Biological Announces 4.98 Billion RMB